N-protected D-leucyl-L-prolyl amide thrombin inhibitor
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticoagulant drugs for treating cardiovascular and cerebrovascular diseases, such as heparin and warfarin, have limitations in efficacy and safety, and there is a need for a novel orally administered thrombin inhibitor that can effectively inhibit thrombin activity with high selectivity and bioavailability.
Innovation Solution
The development of N-carboxylmethyl-D-leucyl-L-prolyl-[(4-amidinophenyl)methyl] amide hydrochloride, a compound that acts as a competitive inhibitor of trypsin-like serine proteases, including thrombin, offering potential as an orally active anticoagulant with improved properties over existing drugs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional anticoagulant drugs such as heparin and warfarin are used, then anticoagulant effect is achieved, but safety and ease of administration deteriorate due to injection requirement, thrombocytopenia risk, and lack of selectivity
Solution Approach 1:
The patent modifies the chemical structure of thrombin inhibitors by changing parameters such as the P3 position amino acid residue (using D-leucine instead of other residues), the P1' position substituent (carboxymethyl group), and stereochemistry (specific D/L configurations). These parameter changes optimize both oral bioavailability and thrombin inhibitory activity while maintaining selectivity, resolving the contradiction between safety and ease of administration.
2Reliability
If traditional anticoagulant drugs are used, then anticoagulant effect is achieved, but selectivity deteriorates leading to individual response variability and monitoring requirements
Solution Approach 1:
The patent applies local quality by designing specific molecular interactions at the thrombin active site. The compound features a P1' carboxymethyl group that forms specific ionic interactions with Asp189 in the thrombin S1' pocket, and a P3 D-leucine residue that fits precisely into the S3 pocket. These localized structural features provide high selectivity for thrombin over other serine proteases, ensuring reliable and predictable clinical effectiveness without the variability seen with warfarin.
3Ease of operation
If orally active thrombin inhibitors are developed, then ease of administration is improved, but bioavailability and activity may deteriorate
Solution Approach 1:
The patent optimizes oral bioavailability by carefully adjusting molecular parameters including the stereochemistry (D-Leu at P3, L-Pro at P1), the basic side chain at P2 (arginine or lysine), and the P1' carboxymethyl substituent. These parameter changes balance molecular size, hydrophobicity, and hydrogen bonding capacity to achieve high oral bioavailability while maintaining potent thrombin inhibitory activity, thereby resolving the contradiction between ease of administration and reliability of bioavailability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This compound demonstrates effective inhibition of thrombin activity, providing a promising treatment for thrombosis and related cardiovascular diseases with enhanced oral bioavailability and safety profile, addressing the limitations of traditional anticoagulants.
Implementation Method 1
This compound is effective in inhibiting the activity of thrombin and is a competitive inhibitor of trypsin-like serine proteases
Data Source
AI summary
Provided are two N-protected D-leucyl-L-prolyl-[(4-amidinophenyl)methyl]amide compounds, pharmaceutically acceptable salts thereof, preparation methods and these compounds for use in inhibiting thrombin, and for use in the treatment and prevention of thrombin-mediated and thrombin-related diseases.